CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors

Figures & data

Figure 1. Schematic representation of selected clinical stage T cell bispecific antibodies: (A) tandem scFv (BiTE) format, (B) asymmetric 1:1 heterodimeric IgG-based TCB, (C) asymmetric 2:1 heterodimeric IgG-based CEA CD3 TCB; (D) Infiltration of CD3⁺ T cells into poorly infiltrated MKN45 tumors in PBMC-engrafted NOG mice treated with vehicle, CEA CD3 TCB and an untargeted control TCB, modified from ⁶ with permission from Clinical Cancer Research.

Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer WF, Lehmann S, Hofer T, Hosse RJ et al. A novel carcinoembryonic antigen t cell bispecific antibody (cea tcb) for the treatment of solid tumors. Clin Cancer Res 2016 Jul 1; 22(13):3286-97; PMID:26861458; http://dx.doi.org/10.1158/1078-0432.CCR-15-1696

 Web of Science ®Google Scholar